Novartis Stops ALS Drug Research
Novartis ended its work on a new drug for ALS after it did not pass an important test, marking another setback for the company.
A glimmer of hope for patients with ALS fades. Novartis, a major drug maker, just announced it stopped research on a new treatment. This news comes after the drug did not work well in a key study.
ALS, also known as Lou Gehrig's disease, slowly takes away a person's ability to move and speak. Finding new ways to fight it is very important. Many companies try to develop new drugs. They aim to give patients more time and a better quality of life.
This marks another challenge for Novartis in its search for new medicines. They have faced other setbacks recently. Developing new drugs is a long and hard process. Companies often test many drugs. Only a few make it to market.
For investors and patients, these outcomes matter. Every failed drug means waiting longer for breakthroughs. Novartis will keep looking for other treatments. The search for cures continues.
Source: FierceBiotech
More from Biotech
